Kobe Minimally Invasive Cancer Center   Report issue

Academic/Hospital Phase 2
Founded: Kobe Japan (2012)

Organization Overview

First Clinical Trial
2019
NCT04153734
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Kobe Minimally Invasive Cancer Center

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Lung Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 5